0001415889-24-016698.txt : 20240613
0001415889-24-016698.hdr.sgml : 20240613
20240613171020
ACCESSION NUMBER: 0001415889-24-016698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240613
DATE AS OF CHANGE: 20240613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peyer James
CENTRAL INDEX KEY: 0001843594
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 241042114
MAIL ADDRESS:
STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC.
STREET 2: 1405 RESEARCH BLVD., STE. 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
form4-06132024_090616.xml
X0508
4
2024-06-11
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001843594
Peyer James
228 PARK AVENUE S. #66643
NEW YORK
NY
10003
true
false
true
false
0
Stock Option (Right to Buy)
0.709
2024-06-11
4
A
0
19000
0
A
2034-06-10
Common Stock
19000
19000
I
See footnote
The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder
meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
These options are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the options, and shares exercisable thereunder, held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such options.
/s/ James Peyer
2024-06-13